Abstract
The MDS/MPN overlap syndromes are recently evolved entities that have been quite difficult to define since their discovery. They have overlapping features with other myeloid neoplasms such as MDS and MPN, which further complicates the task of their diagnosis. The unravelling of their molecular pathogenesis by recent diagnostic innovations was of paramount significance in understanding the mechanism of these syndromes. The identification of the major genetic pathways implicated in their pathogenesis not only will help in their diagnosis, but also will enable development of targeted molecular therapy as well as prognostic markers. This review discus the basic molecular aberrations in MDS/MPN overlap syndromes and their possible future implications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Indian Journal of Hematology and Blood Transfusion
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
